From Sino Biological Inc.Apr 29 2024 , a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext, specializing in biological research reagents and related technical contract research services, has successfully concluded its acquisition of Vancouver-based Canadian biotechnology company SignalChem Biotech Inc. . Sino Biological has acquired 100% of SCB shares in a deal valued at $48 M USD, inclusive of all assets, assumed indebtedness, and net of cash deposits.
SignalChem Biotech Inc. is renowned for its specialized bioactive enzymes, including kinases, proteases, phosphatases, ubiquitin and epigenetic enzymes. Over the past two decades, SCB has established proprietary production and quality control platforms, setting industry standards for the development and production of high-quality bioactive enzyme proteins to support scientists from basic research through drug discovery and development.
The strategic synergy between Sino Biological and SignalChem enables the provision of a broader range of products and research services, supporting the wider life sciences community and facilitating the discovery and development of novel treatments, vaccines and diagnostic platforms. SignalChem is at the scientific forefront of enzyme bioreagent development and production, as well as enzyme-based compound screening technologies. The acquisition of SCB further strengthens Sino Biological’s robust presence in bioactive recombinant proteins and related contract research services, Related Stories"We are excited to join forces with Sino Biological and embark on this new chapter of growth and collaboration," said Mr.
Sino Biological remains committed to maintaining the high standards of quality, reliability, and customer satisfaction throughout the integration process. Customers can expect continued access to the same high-quality products and services they have come to rely on, backed by the combined expertise and resources of Sino Biological and SignalChem Biotech.